Health Alert: New lung cancer studies show immune therapy can improve survival

Patients with advanced lung cancer who received an immunotherapy drug plus standard chemotherapy lived significantly longer than those who got chemo alone, according to a new study that is expected to change the way such patients are treated. The report was one of several highly anticipated studies on immunotherapy and lung cancer presented Monday at the annual meeting of the American Association for Cancer Research in Chicago. The studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the "Super Bowl of lung cancer immunotherapy." The reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.

Democracy Dies in Darkness     Health Alert Mon, Apr 16, 2018, 9:30 AM     New lung cancer studies show immune therapy can improve survival Patients with advanced lung cancer who received an immunotherapy drug plus standard chemotherapy lived significantly longer than those who got chemo alone, according to a new study that is expected to change the way such patients are treated. The report was one of several highly anticipated studies on immunotherapy and lung cancer presented Monday at the annual meeting of the American Association for Cancer Research in Chicago. The studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the "Super Bowl of lung cancer immunotherapy." The reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer. Read more » Advertisement You received this email because you signed up for news alerts from The Washington Post. Manage my newsletters and alerts | Unsubscribe Privacy Policy | Help ©2018 The Washington Post, 1301 K St NW, Washington DC 20071